• Donate
  • Contact
Canadian Association of Pompe
  • Home
  • About Us
    • Portraits of Pompe
    • Our Partners
    • Newsletter
  • About Pompe
    • Webinars
  • Blog
  • Links
  • Connections
Select Page
New Review Article Highlights Latest Developments in Pompe Disease Research

New Review Article Highlights Latest Developments in Pompe Disease Research

by CAP | Sep 20, 2020 | News, Research & Studies

An excellent review article focused on the latest developments in Pompe disease research was recently published by Naresh K. Meena and Nina Raben from the NIH.

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

by Brad Crittenden | Dec 2, 2019 | News

This development should provide Audentes with additional resources for their gene therapy programs, including a Phase 1/2 study for Pompe disease.

Audentes Therapeutics Update on Pompe and Other Programs

Audentes Therapeutics Update on Pompe and Other Programs

by Brad Crittenden | May 7, 2019 | News

Audentes Therapeutics provides updates on their AAV-based genetic medicine program for serious rare neuromuscular diseases.

Amicus Therapeutics Presents Positive Preclinical Pompe Disease Gene Therapy Data

Amicus Therapeutics Presents Positive Preclinical Pompe Disease Gene Therapy Data

by Brad Crittenden | Apr 30, 2019 | News

In what could eventually be very good news for Pompe patients, Amicus Therapeutics presents positive data from their preclinical gene therapy program for Pompe disease.

Amicus Therapeutics establishes a 75,000 sq. ft. Gene Therapy Center of Excellence

Amicus Therapeutics establishes a 75,000 sq. ft. Gene Therapy Center of Excellence

by Brad Crittenden | Mar 5, 2019 | News, Research & Studies

Located in Philadelphia, PA, Amicus Therapeutics is establishing a new Global Research and Gene Therapy Center of Excellence.

Sarepta Therapeutics Enters into a Strategic Relationship with Aldevron in Support of Their Gene Therapy Program

Sarepta Therapeutics Enters into a Strategic Relationship with Aldevron in Support of Their Gene Therapy Program

by Brad Crittenden | Jan 4, 2019 | News

Aldevron will supply plasmid DNA to fulfill Sarepta Therapeutics’s needs for its gene therapy clinical trials and commercial supply.

Audentes Therapeutics Pompe Program Update

Audentes Therapeutics Pompe Program Update

by Brad Crittenden | Nov 28, 2018 | News

Audentes Therapeutics, a gene therapy biotech company, is on track to file an Investigational New Drug (IND) application in 2019 for Pompe disease.

Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies

Amicus Therapeutics Enters Research and Development Collaboration with University of Pennsylvania to Develop AAV Gene Therapies

by Brad Crittenden | Oct 9, 2018 | Press Releases

Focussing on Pompe, Fabry, CDKL5, Amicus Therapeutics begins a collaboration with the Gene Therapy Program at the Perelman School of Medicine at University of Pennsylvania.

Spark Therapeutics Announces New Preclinical Data for Their Pompe Disease Gene Therapy Candidate

Spark Therapeutics Announces New Preclinical Data for Their Pompe Disease Gene Therapy Candidate

by Brad Crittenden | Oct 8, 2018 | Press Releases

Spark Therapeutics announced new preclinical data for SPK-3006, an investigational liver-directed adeno-associated viral (AAV) gene therapy for Pompe disease.

Audentes Therapeutics program update for Pompe disease

Audentes Therapeutics program update for Pompe disease

by Brad Crittenden | Aug 13, 2018 | News

Audentes Therapeutics presented pre-clinical work in support of an IND submission to study AT982 in both infantile and late onset Pompe disease patients.

« Older Entries

Recent Posts

  • Amicus Therapeutics Has Begun the FDA Submission for Their Pompe Drug, AT-GAA
  • New Review Article Highlights Latest Developments in Pompe Disease Research
  • The Genetic Non-Discrimination Act
  • New ERT For Late-onset Pompe Disease Shows Promise
  • 2020 CAP Annual General Meeting
  • Terms
  • Privacy

Copyright © 2006 - 2021 Canadian Association of Pompe | Developed by PacificByte

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok